FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2339356822> ?p ?o ?g. }

• W2339356822 endingPage "33124" @default.
• W2339356822 startingPage "33111" @default.
• W2339356822 abstract "// Marco Perez 1 , Antonio Lucena-Cacace 1 , Luis Miguel Marín-Gómez 1, 2 , Javier Padillo-Ruiz 1, 2 , Maria Jose Robles-Frias 3, 4 , Carmen Saez 1, 3 , Rocio Garcia-Carbonero 5, 6 , Amancio Carnero 1 1 Instituto de Biomedicina de Sevilla, IBIS/Hospital Universitario Virgen del Rocío/ Universidad de Sevilla/Consejo Superior de Investigaciones Científicas, Seville, Spain 2 Department of General Surgery, Virgen del Rocío University Hospital, Seville, Spain 3 Department of Pathology, Virgen del Rocío University Hospital, Seville, Spain 4 Present address: HUVR-IBiS Biobank, Virgen del Rocío University Hospital, Seville, Spain 5 Department of Medical Oncology, Virgen del Rocío University Hospital, Seville, Spain 6 Present address: Department of Medical Oncology, 12 of October University Hospital, Madrid, Spain Correspondence to: Rocio Garcia-Carbonero, email: rgcarbonero@gmail.com Amancio Carnero, email: acarnero-ibis@us.es Keywords: metastatic colorectal carcinoma, cancer treatment, biomarkers, Src kinase, pdx models Received: February 08, 2016      Accepted: March 31, 2016      Published: April 20, 2016 ABSTRACT Despite the development of new antineoplastic agents for the treatment of colorectal cancer (CRC), oxaliplatin and fluoropyrimidines remain the most commonly employed drugs for the treatment of both early and advanced disease. Intrinsic or acquired resistance is, however, an important limitation to pharmacological therapy, and the development of chemosensitization strategies constitute a major goal with important clinical implications. In the present work, we determined that high levels of activated Src kinase, measured as phospho-Src at the Tyr419 residue in CRC cell lines, can promote colorectal carcinoma cell resistance to oxaliplatin, but not to 5-fluorouracil (5FU), and that inhibition of this protein restores sensitivity to oxaliplatin. Similar results were observed with in vivo patient-derived xenograft (PDX) models that were orthotopically grown in murine livers. In PDX tumor lines derived from human CRC liver metastasis, dasatinib, a Src inhibitor, increases sensitivity to oxaliplatin only in tumors with high p-Src. However, dasatinib did not modify sensitivity to 5FU in any of the models. Our data suggest that chemoresistance induced by p-Src is specific to oxaliplatin, and that p-Src levels can be used to identify patients who may benefit from this combination therapy. These results are relevant for clinicians as they identify a novel biomarker of drug resistance that is suitable to pharmacological manipulation." @default.
• W2339356822 created "2016-06-24" @default.
• W2339356822 creator A5005444342 @default.
• W2339356822 creator A5019132484 @default.
• W2339356822 creator A5031770911 @default.
• W2339356822 creator A5043828184 @default.
• W2339356822 creator A5049859249 @default.
• W2339356822 creator A5063985660 @default.
• W2339356822 creator A5065864417 @default.
• W2339356822 creator A5091354337 @default.
• W2339356822 date "2016-04-20" @default.
• W2339356822 modified "2023-10-18" @default.
• W2339356822 title "Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src" @default.
• W2339356822 cites W13907802 @default.
• W2339356822 cites W1504053030 @default.
• W2339356822 cites W1532635242 @default.
• W2339356822 cites W1548379836 @default.
• W2339356822 cites W1862926318 @default.
• W2339356822 cites W186486613 @default.
• W2339356822 cites W1963570775 @default.
• W2339356822 cites W1970213932 @default.
• W2339356822 cites W1971333743 @default.
• W2339356822 cites W1972035895 @default.
• W2339356822 cites W1975954014 @default.
• W2339356822 cites W1978165300 @default.
• W2339356822 cites W1988212593 @default.
• W2339356822 cites W1992716524 @default.
• W2339356822 cites W1995083340 @default.
• W2339356822 cites W2000868207 @default.
• W2339356822 cites W2023500337 @default.
• W2339356822 cites W2024161072 @default.
• W2339356822 cites W2026763872 @default.
• W2339356822 cites W2027206279 @default.
• W2339356822 cites W2030565228 @default.
• W2339356822 cites W2034368878 @default.
• W2339356822 cites W2041191688 @default.
• W2339356822 cites W2043675304 @default.
• W2339356822 cites W2044333356 @default.
• W2339356822 cites W2046163031 @default.
• W2339356822 cites W2054177711 @default.
• W2339356822 cites W2054466658 @default.
• W2339356822 cites W2061953474 @default.
• W2339356822 cites W2071756286 @default.
• W2339356822 cites W2078104880 @default.
• W2339356822 cites W2092343827 @default.
• W2339356822 cites W2096045656 @default.
• W2339356822 cites W2108426094 @default.
• W2339356822 cites W2117844134 @default.
• W2339356822 cites W2119168587 @default.
• W2339356822 cites W2130177169 @default.
• W2339356822 cites W2134589965 @default.
• W2339356822 cites W2136103100 @default.
• W2339356822 cites W2136929338 @default.
• W2339356822 cites W2139639159 @default.
• W2339356822 cites W2143060756 @default.
• W2339356822 cites W2143974518 @default.
• W2339356822 cites W2147545245 @default.
• W2339356822 cites W2153034562 @default.
• W2339356822 cites W2156147330 @default.
• W2339356822 cites W2158853280 @default.
• W2339356822 cites W2161339168 @default.
• W2339356822 cites W2171629680 @default.
• W2339356822 cites W2342671164 @default.
• W2339356822 cites W27535306 @default.
• W2339356822 cites W6610818 @default.
• W2339356822 doi "https://doi.org/10.18632/oncotarget.8880" @default.
• W2339356822 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5363656" @default.
• W2339356822 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28074043" @default.
• W2339356822 hasPublicationYear "2016" @default.
• W2339356822 type Work @default.
• W2339356822 sameAs 2339356822 @default.
• W2339356822 citedByCount "25" @default.
• W2339356822 countsByYear W23393568222017 @default.
• W2339356822 countsByYear W23393568222018 @default.
• W2339356822 countsByYear W23393568222019 @default.
• W2339356822 countsByYear W23393568222020 @default.
• W2339356822 countsByYear W23393568222021 @default.
• W2339356822 countsByYear W23393568222022 @default.
• W2339356822 crossrefType "journal-article" @default.
• W2339356822 hasAuthorship W2339356822A5005444342 @default.
• W2339356822 hasAuthorship W2339356822A5019132484 @default.
• W2339356822 hasAuthorship W2339356822A5031770911 @default.
• W2339356822 hasAuthorship W2339356822A5043828184 @default.
• W2339356822 hasAuthorship W2339356822A5049859249 @default.
• W2339356822 hasAuthorship W2339356822A5063985660 @default.
• W2339356822 hasAuthorship W2339356822A5065864417 @default.
• W2339356822 hasAuthorship W2339356822A5091354337 @default.
• W2339356822 hasBestOaLocation W23393568221 @default.
• W2339356822 hasConcept C121608353 @default.
• W2339356822 hasConcept C126322002 @default.
• W2339356822 hasConcept C143998085 @default.
• W2339356822 hasConcept C170493617 @default.
• W2339356822 hasConcept C2779536868 @default.
• W2339356822 hasConcept C2779786085 @default.
• W2339356822 hasConcept C2780962732 @default.
• W2339356822 hasConcept C2781187634 @default.
• W2339356822 hasConcept C42362537 @default.
• W2339356822 hasConcept C526805850 @default.

• next